QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
NASDAQ:IART

Integra LifeSciences - IART Stock Forecast, Price & News

$54.03
+0.59 (+1.10%)
(As of 03/20/2023 12:00 AM ET)
Add
Compare
Today's Range
$53.61
$54.84
50-Day Range
$52.61
$60.49
52-Week Range
$40.67
$67.14
Volume
478,747 shs
Average Volume
503,603 shs
Market Capitalization
$4.41 billion
P/E Ratio
25.01
Dividend Yield
N/A
Price Target
$58.17

Integra LifeSciences MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
7.7% Upside
$58.17 Price Target
Short Interest
Healthy
6.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.50
Upright™ Environmental Score
News Sentiment
0.17mentions of Integra LifeSciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$314,775 Sold Last Quarter
Proj. Earnings Growth
9.77%
From $3.48 to $3.82 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

672nd out of 988 stocks

Surgical & Medical Instruments Industry

66th out of 101 stocks


IART stock logo

About Integra LifeSciences (NASDAQ:IART) Stock

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

IART Stock News Headlines

The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Citigroup Keeps Their Hold Rating on Integra Lifesciences (IART)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Integra LifeSciences Holdings Q4 2022 Earnings Preview
What 6 Analyst Ratings Have To Say About Integra Lifesciences
See More Headlines
Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

IART Company Calendar

Last Earnings
2/22/2023
Today
3/20/2023
Next Earnings (Estimated)
4/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IART
CUSIP
45798520
Employees
3,722
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$58.17
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+7.7%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$180.55 million
Pretax Margin
13.73%

Debt

Sales & Book Value

Annual Sales
$1.56 billion
Cash Flow
$4.91 per share
Book Value
$21.57 per share

Miscellaneous

Free Float
78,207,000
Market Cap
$4.41 billion
Optionable
Optionable
Beta
1.13

Social Links


Key Executives

  • Jan D. de Witte
    President, Chief Executive Officer & Director
  • Steve Leonard
    Vice President-Global Operations & Supply Chain
  • Jeffrey Alan MosebrookJeffrey Alan Mosebrook
    Senior Vice President-Finance & PAO
  • William Compton
    Chief Information Officer & Senior Vice President
  • Stuart Hart
    Chief Medical Officer & Vice President













IART Stock - Frequently Asked Questions

Should I buy or sell Integra LifeSciences stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" IART shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View IART analyst ratings
or view top-rated stocks.

What is Integra LifeSciences' stock price forecast for 2023?

5 equities research analysts have issued 12-month price targets for Integra LifeSciences' shares. Their IART share price forecasts range from $48.00 to $75.00. On average, they anticipate the company's share price to reach $58.17 in the next twelve months. This suggests a possible upside of 7.7% from the stock's current price.
View analysts price targets for IART
or view top-rated stocks among Wall Street analysts.

How have IART shares performed in 2023?

Integra LifeSciences' stock was trading at $56.07 at the beginning of 2023. Since then, IART shares have decreased by 3.6% and is now trading at $54.03.
View the best growth stocks for 2023 here
.

Are investors shorting Integra LifeSciences?

Integra LifeSciences saw a drop in short interest in the month of February. As of February 28th, there was short interest totaling 4,770,000 shares, a drop of 12.2% from the February 13th total of 5,430,000 shares. Based on an average trading volume of 490,300 shares, the days-to-cover ratio is currently 9.7 days. Approximately 6.7% of the shares of the company are short sold.
View Integra LifeSciences' Short Interest
.

When is Integra LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our IART earnings forecast
.

How were Integra LifeSciences' earnings last quarter?

Integra LifeSciences Holdings Co. (NASDAQ:IART) issued its quarterly earnings results on Wednesday, February, 22nd. The life sciences company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.01. The life sciences company had revenue of $398 million for the quarter, compared to analysts' expectations of $398.57 million. Integra LifeSciences had a net margin of 11.59% and a trailing twelve-month return on equity of 16.51%. The company's revenue for the quarter was down 1.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.84 earnings per share.

When did Integra LifeSciences' stock split?

Integra LifeSciences shares split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were distributed to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Integra LifeSciences issued on next quarter's earnings?

Integra LifeSciences updated its FY23 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share (EPS) guidance of $3.43-3.51 for the period, compared to the consensus earnings per share estimate of $3.53. The company issued revenue guidance of $1.602-1.620 billion, compared to the consensus revenue estimate of $1.62 billion.

What is Peter J. Arduini's approval rating as Integra LifeSciences' CEO?

173 employees have rated Integra LifeSciences Chief Executive Officer Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Integra LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

What is Integra LifeSciences' stock symbol?

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Who are Integra LifeSciences' major shareholders?

Integra LifeSciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (3.47%), Cooke & Bieler LP (3.27%), Clearbridge Investments LLC (3.09%), Fuller & Thaler Asset Management Inc. (1.81%), Dimensional Fund Advisors LP (1.44%) and Geode Capital Management LLC (1.27%). Insiders that own company stock include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Raymond G Murphy, Richard E Caruso, Stuart Essig and Tru St Partnership, LP.
View institutional ownership trends
.

How do I buy shares of Integra LifeSciences?

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Integra LifeSciences' stock price today?

One share of IART stock can currently be purchased for approximately $54.03.

How much money does Integra LifeSciences make?

Integra LifeSciences (NASDAQ:IART) has a market capitalization of $4.41 billion and generates $1.56 billion in revenue each year. The life sciences company earns $180.55 million in net income (profit) each year or $2.16 on an earnings per share basis.

How many employees does Integra LifeSciences have?

The company employs 3,722 workers across the globe.

Does Integra LifeSciences have any subsidiaries?
The following companies are subsidiares of Integra LifeSciences: ACell Inc, ACell Inc., Arkis BioSciences, Arkis Biosciences Inc., Ascension Orthopedics Inc., Ascension Orthopedics Limited, BIMECO Inc., BioD LLC, BioDlogics LLC, BioRecovery LLC, CardioDyne Inc., Cathtec Incorporated, Caveangle Limited, Codman Neuro, Confluent Surgical, Confluent Surgical Inc., Derma First Aid Products Inc., Derma Sciences, Derma Sciences Canada Inc., Derma Sciences Europe Limited, Derma Sciences Inc., EndoSolutions Inc., Fiber Imaging Technologies Inc., GMS Gesellschaft für medizinische Sondentechnik mbH, ILS Financing (Ireland) Limited, ILS Financing Corporation, ILS Services Switzerland Ltd., ILS Surgical Investments LLC, INS Sweden AB, Integra Burlington MA Inc., Integra CI Inc., Integra Canada ULC, Integra Euro Holdings Inc., Integra France Holdings SAS, Integra German Holdings GmbH, Integra GmbH, Integra Japan K.K., Integra LS (Benelux) NV, Integra LS Mexico S. DE R. L. DE C.V., Integra LifeSciences (Canada) Holdings Inc., Integra LifeSciences (Ireland) Limited, Integra LifeSciences (Shanghai) Co. Ltd., Integra LifeSciences Austria GmbH, Integra LifeSciences Brazil Ltda., Integra LifeSciences Corporation, Integra LifeSciences Enterprises LLLP, Integra LifeSciences Financing (Cyprus) Limited, Integra LifeSciences Italy S.r.l., Integra LifeSciences Middle East FZ-LLC, Integra LifeSciences Production Corporation, Integra LifeSciences Sales LLC, Integra LifeSciences Services (France) SAS, Integra LifeSciences Shared Services (Ireland) Limited, Integra LifeSciences Singapore Pte. Ltd., Integra LifeSciences Spain S.L., Integra LifeSciences Switzerland Sárl, Integra Luxtec Inc., Integra ME GmbH, Integra MicroFrance SAS, Integra NeuroSciences (International) Inc., Integra NeuroSciences Holdings (UK) Limited, Integra NeuroSciences Holdings B.V., Integra NeuroSciences Implants (France) SAS, Integra NeuroSciences Limited, Integra Neurosciences, Integra Neurosciences Pty Ltd. (AUS), Integra Neurosciences Pty Ltd. (NZ), Integra Receivables LLC, Integra Sales Inc., Integra Selector LLC, Integra Switzerland Holdings Sarl, Integra York PA Inc., IsoTis NV, IsoTis T.E. Facility B.V., J. Jamner Surgical Instruments Inc., Jarit GmbH, Kinetikos Medical, Koby Ventures II L.P. dba Metasurg, LXU Healthcare Inc. - Medical Specialty Products, MedEfficiency Inc., Medtronic Xomed Instrumentation SAS, Miltex, Minnesota Scientific Inc., Nantong Derma Medical Products Co. Ltd., Newdeal Inc., Newdeal SAS, Omni-Tract, Precise Dental Holding Corp., Precise Dental Internacional S.A. de C.V., Precise Dental Products Ltd., Precision Dental International Inc., Rebound Therapeutics, Rebound Therapeutics Corporation, Spembly Cryosurgery Limited, Spembly Medical Limited, TEI Biosciences (UK) Limited, TEI Biosciences Inc., TEI Biosciences Inc., TEI Medical Inc., TGX Medical Systems, TGX Medical Systems LLC, Tarsus Medical Inc., Tarsus Medical Inc., Tekmed Instruments S.p.A, Theken Disc, Theken Spine, and Therics.
Read More
How can I contact Integra LifeSciences?

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The official website for the company is www.integralife.com. The life sciences company can be reached via phone at (609) 275-0500, via email at ir@integralife.com, or via fax at 609-750-4277.

This page (NASDAQ:IART) was last updated on 3/20/2023 by MarketBeat.com Staff